A novel Bcl-2/Bcl-XL inhibitor APG-1252-12A as a potential therapeutic strategy for gastric carcinoma

被引：0

作者：

Yan, Xianglei ^{[1
]}

Yi, Hanjie ^{[1
]}

Luo, Qiuyun ^{[1
]}

Yuan, Luping ^{[1
]}

Zhou, Suna ^{[1
]}

Pan, Wentao ^{[2
]}

Zhang, Lin ^{[1
]}

Qiu, Miaozhen ^{[1
]}

Yang, Dajun ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China

[2] Ascentage Pharma Inc, Suzhou, Peoples R China

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-2054

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2054

引用

页数：2

共 50 条

[1] Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma
Yi, Hanjie
Qiu, Miao-Zhen
Yuan, Luping
Luo, Qiuyun
Pan, Wentao
Zhou, Suna
Zhang, Lin
Yan, Xianglei
Yang, Da-Jun
CANCER MEDICINE, 2020, 9 (12): : 4197 - 4206
[2] Therapeutic potential of the novel Bcl-2/Bcl-XL dual inhibitor, APG1252, alone or in combination against non-small cell lung cancer
Qian, Luxi
Vallega, Karin A.
Yao, Weilong
Wang, Dongsheng
Zhai, Yifan
He, Xia
Sun, Shi-Yong
MOLECULAR CARCINOGENESIS, 2022, 61 (11) : 1031 - 1042
[3] APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells
Wang, Jing
Yang, Dajun
Luo, Qiuyun
Qiu, Miaozhen
Zhang, Lin
Li, Baoxia
Chen, Haibo
Yi, Hanjie
Yan, Xianglei
Li, Shuxia
Sun, Jian
INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 51 (02) : 563 - 572
[4] A Phase I Study of Novel Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced SCLC or Other Solid Tumor
Wu, Y.
Lakhani, N. J.
Boyer, M.
Zhou, Q.
Rasco, D. W.
Huang, Y.
Men, L.
Li, Y.
Xia, Z.
Wang, H.
Ji, J.
Lu, B.
He, Z.
Dong, Q.
Yang, D.
Zhai, Y.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1048 - S1049
[5] Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells
Yamamoto, Leona
Derebail, Sanika
Aktas-Samur, Anil
Hideshima, Teru
Chyra, Zuzana
Chakraborty, Chandraditya
Yao, Yao
Gramegna, Doriana
Morelli, Eugenio
Samur, Mehmet K.
Deng, Jing
Zhai, Yifan
Gulla, Annamaria
Fulciniti, Mariateresa
Anderson, Kenneth C.
Munshi, Nikhil C.
BLOOD, 2021, 138
[6] BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity
Bai, L.
Chen, J.
Liu, L.
McEachern, D.
Aguilar, A.
Zhou, H.
Yang, C. Y.
Wang, H.
Wen, J.
Wang, G.
Zhai, Y.
Guo, M.
Yang, D.
Wang, S.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : 109 - 110
[7] Combination of BCL-2/BCL-xL dual inhibitor APG-1252 and chemotherapeutics overcomes resistance to osimertinib in EGFR mutant NSCLC in preclinical models
Tao, Ran
Wang, Guangfeng
Fang, Douglas D.
Zhai, Guoqin
Li, Yuanbao
Lv, Jing
Wu, Miaoyi
Ge, Yangfeng
Zhang, Feifei
Wen, Danyi
Yang, Dajun
Zhai, Yifan
CANCER RESEARCH, 2020, 80 (16)
[8] The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer
Luo, Qiu-yun
Yang, Jing
Di, Tian
Xia, Zeng-fei
Zhang, Lin
Pan, Wen-tao
Shi, Shan
Yang, Li-qiong
Sun, Jian
Qiu, Miao-zhen
Yang, Da-jun
ACTA PHARMACOLOGICA SINICA, 2024, : 1082 - 1096
[9] A Potent and Highly Efficacious Bcl-2/Bcl-xL Inhibitor
Aguilar, Angelo
Zhou, Haibin
Chen, Jianfang
Liu, Liu
Bai, Longchuan
McEachern, Donna
Yang, Chao-Yie
Meagher, Jennifer
Stuckey, Jeanne
Wang, Shaomeng
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (07) : 3048 - 3067
[10] Targeting BCL-2 and BCL-xL with a novel dual inhibitor APG-1252 triggers cell death and inhibits tumor growth in small cell lung cancer models
Wang, GuangFeng
Min, Ping
Wu, MiaoYi
Dang, Shuo
Tang, ChuanYan
Zhang, Fei
Guo, Ming
Wang, Shaomeng
Deng, Jing
Fang, Douglas D.
Yang, DaJun
Zhai, YiFan
CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →